TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03936842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Pain video
Description: An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semi-structure interviews
Description: A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
Study: NCT04513743

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24/7 EEG™ SubQ
Description: 24/7 EEG™ SubQ device will be worn by each subject for 365 nights
Study: NCT06147492

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transanal total mesorectal excision
Description: a transanal bottom-up approach was employed for the TME procedure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Total Mesorectal Excision
Description: Laparoscopic Total Mesorectal Excision

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Total Mesorectal Excision
Description: Laparoscopic Total Mesorectal Excision
Study: NCT04264546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study: NCT00777998

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI
Description: \*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> 2 months later: Melphalan plus allogeneic PBSCT~* -\> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~* -\> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10\^6 (MRD) or 5 x 10\^5 (MUD) CD3+ cells per kg BW)~* -\> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~* -\> Further DLI depending on MRD-measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide
Description: \*Multiple myeloma~* -\> Induction Therapy (max. 8 cycles)~* -\> Registration of patient, stem cell mobilization, start of donor search~* -\> Melphalan (200mg/qm) plus autologous PBSCT~* -\> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~* -\> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)
Study: NCT03084276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: High-fat meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat meal
Description: Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
Study: NCT03469726

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast-enhanced Diffusion-weighted MRI
Description: An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
Study: NCT01851707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
Study: NCT02412579

Intervention type: OTHER
Intervention: None - Standard of Care
Study: NCT00479830

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
Study: NCT03519919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A multifocal lens
Description: contact lens
Study: NCT03910140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TILA-TACE treatment
Description: TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
Study: NCT03578445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided microbiopsy
Description: Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Generation Sequencing
Description: Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
Study: NCT02333994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GROUP A education programme as well as balance training exercises
Description: Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
Study: NCT02333994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B on-platform training
Description: on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
Study: NCT00255840

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring by an HIV-trained medical doctor
Description: Participants will receive care from an HIV-trained medical doctor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring by an HIV-trained primary care nurse
Description: Participants will receive care from an HIV-trained primary care nurse

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg tablet taken orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 150 mg tablet taken orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 150 mg tablet taken orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100mg ritonavir tablet taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100mg ritonavir tablet taken orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: 200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Tablet taken orally daily. Dosage depends on weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: Tablet taken orally daily. Dosage depends on weight.
Study: NCT04365673

Intervention type: OTHER
Intervention: Pharmacist transition of care consultation
Description: Pharmacist-delivered comprehensive medication review

Intervention type: OTHER
Intervention: Pharmacist transition of care consultation
Description: Pharmacist-delivered comprehensive medication review
Study: NCT04361760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-puls TMS
Description: Medical Device (MD): MagPro X100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-puls TMS
Description: Medical Device (MD): MagPro X100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: Sham stimulation is delivered with a dedicated coil, which is magnetically shielded and thus produces only approx. 20% of the nominal magnetic field. This is not enough to reach and stimulate the cortex, but the produced sound and scalp sensation are the same as with a real TMS coil.
Study: NCT04401202

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Description: Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
Study: NCT02671617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Description: Preoperative HIIT protocol.
Study: NCT00561535

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus FARCIMINIS
Description: 10.10 UFC of lactobacillus FARCIMINIS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (starch)
Description: Once daily
Study: NCT01838772

Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated-Interferon and Ribavirin
Description: This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
Study: NCT04053244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioural therapy
Description: Designed for general clinical use (but not specifically cardiac patients), it consists of 5 online modules outlining cognitive-behavioural skills for depression, completed over 7-8 weeks. The participants will be guided step-wise through the modules by the therapist. Participants can work more or less at their own pace, but are expected to proceed to the next module within 1-2 weeks. Because the content is identical for each participant, fidelity to the web-based component of the intervention is ensured.
Study: NCT00966732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga of Awareness Program
Description: The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
Study: NCT03825822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPaC Resource Intervention (INT)
Description: A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Practice (SP)
Description: The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
Study: NCT02710552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tripliam (perindopril, indapamide, amlodipine)
Description: Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reaptan (perindopril, amlodipine)
Description: Fixed combination of perindopril 10 mg and amlodipine 5 mg
Study: NCT00560482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABR-215050, tasquinimod
Description: Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical appearing gelatin capsules containing placebo
Study: NCT02139774

Intervention type: BEHAVIORAL
Intervention: Walk with Ease
Description: A six week walking program by the Arthritis Foundation
Study: NCT00520845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood collection
Study: NCT02751047

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual ventilation
Description: Facemask ventilation is performed by manual bagging with reservoir bag.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure controlled mechanical ventilation
Description: Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
Study: NCT00387959

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study: NCT01015677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-β estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-6913

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-6913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to 17-β estradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 17-β estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6913 25 mg
Study: NCT01580904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Pharmaceutical Care
Description: Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
Study: NCT02603692

Intervention type: OTHER
Intervention: PROMIS-QOL
Description: PROMIS questionnaires completed every 3 months for up to 2 years.

Intervention type: OTHER
Intervention: PROMIS-QOL
Description: PROMIS questionnaires completed every 3 months for up to 2 years.

Intervention type: OTHER
Intervention: PROMIS-QOL
Description: PROMIS questionnaires completed every 3 months for up to 2 years.
Study: NCT01732549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
Study: NCT03432468

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan 1
Description: the high dose of valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 1
Description: the high dose of valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: a single dose of valsartan
Study: NCT04231045

Intervention type: DEVICE
Intervention: PiCCO device cardiac monitoring
Description: PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated
Study: NCT02232399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Study: NCT01660256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759
Description: Instillation, 4 times/day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-12759
Description: Instillation, 4 times/day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02885662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 2.5 to 5.0 mg , orally.
Study: NCT02691988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICS withdrawal
Description: Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)